Anavex Life Sciences Corp. (AVXL) financial statements (2023 and earlier)

Company profile

Business Address 51 W 52ND STREET,
NEW YORK, NY 10019-6163
State of Incorp. NV
Fiscal Year End September 30
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments151,146152,10829,24922,18622,93127,440
Cash and cash equivalents151,146152,10829,24922,18622,93127,440
Receivables5,3729,1374,8492,643  
Prepaid expense 356444 1,252336
Other undisclosed current assets   50114110
Total current assets:156,519161,60034,54225,32924,32427,786
Noncurrent Assets
Regulated entity, other noncurrent assets 16    
Deposits noncurrent assets    5252
Total noncurrent assets: 16  5252
Other undisclosed assets378     
TOTAL ASSETS:156,896161,61634,54225,32924,37627,838
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:10,08510,3557,3065,0403,8853,584
Accounts payable4,6354,7403,9893,523  
Accrued liabilities5,4505,6153,3171,516  
Other undisclosed accounts payable and accrued liabilities    3,8853,584
Deferred revenue444   
Total current liabilities:10,52910,3557,3065,0403,8853,584
Noncurrent Liabilities
Other undisclosed liabilities 444    
Total liabilities:10,52910,7987,3065,0403,8853,584
Stockholders' equity
Stockholders' equity attributable to parent146,368150,81827,23720,29020,49224,254
Common stock767662534643
Additional paid in capital354,760348,328186,852153,634129,378115,689
Accumulated deficit(208,468)(197,586)(159,677)(133,397)(108,932)(91,479)
Total stockholders' equity:146,368150,81827,23720,29020,49224,254
TOTAL LIABILITIES AND EQUITY:156,896161,61634,54225,32924,37627,838

Income statement (P&L) ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
Revenues444444    
Other income 444    
Gross profit: 444    
Operating expenses(44,328)(42,001)(31,088)(29,107)(19,334)(15,680)
Other undisclosed operating income444     
Operating loss:(43,885)(41,557)(31,088)(29,107)(19,334)(15,680)
Nonoperating income3,6314,3604,8302,8941,9532,280
Foreign currency transaction gain (loss), before tax(545)(267)126(42)(50)(48)
Interest and debt expense   116(31) 
Other undisclosed loss from continuing operations before equity method investments, income taxes(444)(444) (116)  
Loss from continuing operations before equity method investments, income taxes:(40,698)(37,641)(26,258)(26,213)(17,412)(13,401)
Other undisclosed income from continuing operations before income taxes    31 
Loss from continuing operations before income taxes:(40,698)(37,641)(26,258)(26,213)(17,381)(13,401)
Income tax expense(506)(535)(23)(82)(73)(60)
Net loss:(41,204)(38,176)(26,280)(26,295)(17,453)(13,460)
Other undisclosed net income attributable to parent268268    
Net loss available to common stockholders, diluted:(40,936)(37,909)(26,280)(26,295)(17,453)(13,460)

Comprehensive Income ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
Net loss:(41,204)(38,176)(26,280)(26,295)(17,453)(13,460)
Comprehensive loss, net of tax, attributable to parent:(41,204)(38,176)(26,280)(26,295)(17,453)(13,460)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: